CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) reported on two preclinical studies that demonstrated the potential of indium-111-edotreotide as an imaging tool to predict Onalta (yttrium-90-edotreotide) absorption in body tissues and to aid in determining appropriate patient dose. Onalta is in development as a targeted radiotherapeutic for the treatment of carcinoid and pancreatic neuroendocrine tumors. The in vitro and in vivo studies are part of Molecular Insight’s clinical program to support a planned U.S. dosimetry trial later this year. Results were presented at the Society of Nuclear Medicine (SNM) 55th Annual Meeting in New Orleans, LA.
